MaxCyte today
As of 01.24.2025 16:00 East
- 52-week range
- $ 3.16
▼
$ 5.29
- Target price
- 9.50 US dollars
Maksit INC. Nasdak: MXCT – Global developer of new generation cell therapy. They provide the most important technologies for cellular and gene therapy. Their main tools of Expert ATX, STX, GTX and VLX use a patented technology called Flow Electroporation, which was optimized for safe and effective cell engineering.
The medical sector company allowed biotechnological companies to develop and bring revolutionary methods of treatment to the market. MaxCyte technology helped Veretex Farmasyutikals Inc. Nasdak: VRTX And CRISPR Therapeutics AG Nasdak: CRSP To develop the first in the world approved FDA Method for editing genes for the treatment of sickle cell anemia (SCD), Casgevy.
What is the technology of prototype electrores?
The technology of prototype electropulation of MaxCyte allows the developers of drugs to effectively introduce genetic material into cells, such as RNA and DNA. In cell therapy, they help create immune cells, such as Car-T cells, to combat cancer. Genes editing tools, such as CRISPR/CAS-9 molecular scissors, help to fix genetic defects. It is also effective for developing vaccines and opening drugs.
Development of caszhevi for successful editing genes
MaxCyte proto-button electropoling technology delivers CRISPR/CAS-9 editing tools to the patient. The technology uses electrical impulses to create temporary pores in the cell membrane, which allows genes to edit tools to effectively penetrate the cells. MaxCyte technology guarantees successful editing a large number of T cells using CRISPR/CAS-9 molecular scissors, which is crucial for the effectiveness of therapy.
Casgevy allows CRISPR/CAS-9 to edit the BCL11A gene in stem cells for the production of fetal hemoglobin. The edited genes are introduced into the patient’s bone marrow to begin to produce red blood cells with a high level of fetal hemoglobin, preventing the sickle formation of red blood cells, reducing the frequency and severity of vaso -cluster crises and other complications associated with BCS.
MaxCyte increases the forecast for the fourth quarter due to SPL income
MaxCyte sells electroption tools and a strategic platform license (SPL). According to MaxCyte, the net cost (NPV) SPL is $ 85 million. The company has 29 active SPL, which involves a potential unforeseen profit of 2.4 billion dollars, if all treatment methods are approved by FDA. On January 13, 2025, MaxCyte increased the prognosis for revenue to $ 8.3–8.5 million compared to a consensus of analysts of $ 7.77 million.
MaxCyte shares forecast today
9.50 US dollars
Growth potential 103.86%Buy
Based on ratings of 3 analysts
| High forecast | 11.00 US dollars |
|---|---|
| Average forecast | 9.50 US dollars |
| Low forecast | 8.00 US dollars |
Details of forecast for MaxCyte shares
It is expected that the revenue for 2024 will be from 32.2 to 32.4 million dollars against $ 29.8 million for the same period last year. This is an increase in income associated with SPL by 8–9%. Cash and their equivalents from the company amount to $ 190 million compared to the initial forecast of $ 175 million.
MAXCYTE General Director Maher Masud commented on his profits and losses for the third quarter of 2024: “In 2024, we signed six new SPLs, which is a record number of new SPL customers in one year for MaxCyte. Our last signed SPL, Kamau Therapeutics, brought the total number of our SPL to 29. We are very inspired by the progress of our customers in their programs and are still focused on providing them with the best possible support in their development efforts. ”
Masud concluded: “Since we are expanding our technology for a larger number of customers and programs, the Expert platform supports the growing number of technologies that require numerous changes and stages, as well as treatment methods for a number of new indications.”
MXCT provokes a breakthrough of a bull flag
The pattern of the bull flag consists of two parts. Firstly, the basic action forms a flagpole, which is a sharp jump in the price of a share, usually at an angle of 45 degrees or higher. The flagpole ends when the action reaches its peak. The flag is formed on parallel descending lines of the trend consisting of all lower maximums. The bull flag works when the action overcomes the upper descending line of the trend and goes through the top of the flagpole.
MXCT formed a bull breakthrough after overcoming the descending upper resistance line at 4.07 dollars. Daily tied VWAP support increases to $ 4.06. An increased forecast contributed to a breakthrough. Daily RSI grows at 65. Fibonacci (Fibonacci pumping levels are at 4.56, 4.33, 3.97 and 3.71 dollars.
The average target price of MXCT shares is 92.31% higher 9.50 US dollarsAnd his highest target price for analysts is at the level 11 US dollars. He has the recommendation to “buy” from three analysts. A short interest rate on shares is 3.14%.
Effective optional strategies: Bull investors with longer time frames who want to spend less capital can consider the possibility of a directed purchase outside of money (OTM). Jumping Call options for maximizing profit.
Before considering MaxCyte, you should hear it.
MarketBeat tracks the most rating and effective Wall Street analysts daily, as well as promotions that they recommend to their customers. Marketbeat has identified five shares that leading analysts quietly advise their customers to buy now before the wider market has gained popularity … and MaxCyte was not on the list.
Although MaxCyte currently has a rating of “buying” among analysts, analysts with the highest rating believe that these five promotions are better to buy.
View five shares here
Market downtime make many investors think, and not without reason. Want to know how to compensate for this risk? Enter your email address to learn more about the use of beta versions to protect your portfolio.
Get this free report